With its announcement on Thursday that it will acquire biotech bellwether Celgene, Bristol-Myers Squibb has placed a very big bet: that it is worth $74 billion to combine its cancer drugs with Celgene’s.

“We’ve taken our strategic foundation to be the best of biotech and the best of pharma as a company,” Bristol Chairman and Chief Executive Giovanni Caforio told me.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • “When one looks broadly at cancer immunotherapy, there are four big areas, he argued: drugs like Opdivo and Keytruda; medicines like Bristol’s Yervoy; medicines that make use of a protein called IL-2, such as one Bristol licensed from Nektar; and cell therapies such as the ones it just acquired in its Celgene buy.”

    That strikes me as an exceedingly arbitrary categorization of IO therapies – salesmanship around the combined BMY / CELG asset base reinforces the notion that this deal is the result of a push for growth at any cost.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy